Table 1.

GR antagonists diminish cell survival and tumor metastasis functions while promoting cell death and differentiation.

Cell function		Activation Z-score			Treatment time (hr)	Number of genes (n)
		Dex	DexMif	Dex297
Dex-activated pathways	synthesis of lipid	1.91	0.68	0.83	4	46
	invasion of tumor cell lines	0.63	−0.03	0.35	4	53
	colony formation of tumor cell lines (invasion)	0.14	0.02	−0.52	4	24
	epithelial-mesenchymal transition of breast cell lines	0.11	−0.34	−0.22	4	9
	metastasis of tumor cell lines	2.05	1.03	1.22	8	16
	transactivation	1.62	−0.44	−0.28	8	39
	cell survival	1.53	−1.28	0.69	8	99
	cell proliferation of colorectal cancer cell lines	0.72	−1.23	−0.71	8	27
	cell transformation	0.22	−1.55	−1.29	8	42
	invasion of tumor cells	1.43	0.26	0.29	12	15
	growth of tumor	0.77	0.47	0.24	12	63
	growth of blood vessel	0.44	−0.44	0.22	12	10
Dex-inactivated pathways	cell death of tumor cells	−1.57	−0.55	−0.3	4	35
	cytostasis of tumor cell lines	−1.6	0.77	1.03	4	15
	contact growth inhibition of tumor cell lines	−1.77	0.09	0.52	4	13
	benign neoplasia	−2.35	−0.03	−1.49	4	63
	inflammatory response	−0.14	2.12	1.94	8	54
	cytostasis of tumor cell lines	−1.01	−0.45	0.35	8	15
	contact growth inhibition of tumor cell lines	−1.02	−0.39	0.51	8	13
	apoptosis	−1.06	0.41	1.11	8	162
	cell death	−2.27	0.45	0.26	8	193
	development of epithelial tissue (differentiation)	−1.69	0.19	−1.22	12	45